高危早期子宫内膜癌肿瘤分子分型的成本-效果分析
本研究采用马尔可夫决策模型,从医疗支付方视角、以5年时间跨度,比较高危I–II期子宫内膜癌患者接受肿瘤分子分型检测(TMC)与不检测(NT)的成本-效果。与NT相比,TMC具有成本效果,ICER为每获得1个QALY 25578美元,增量成本1780美元,增量效果0.070 QALYs;单因素敏感性分析中结果对POLE检测成本最敏感,但在所有参数范围内TMC均保持成本效果。
要点
- 与不检测相比,TMC的ICER为每QALY 25578美元,低于100000美元/QALY的支付意愿阈值。
- TMC的增量成本为1780美元,增量效果为0.070 QALYs。
- 单因素敏感性分析中结果对POLE检测成本最敏感,但TMC在所有参数范围内仍具成本效果。
核心结论
- 在高危早期子宫内膜癌中,肿瘤分子分型检测具有成本效果,且模型结果在一系列参数范围内稳健。
- 鉴于分子分型可用于指导辅助治疗决策,这些发现支持将肿瘤分子分型检测纳入常规实践。
研究设计与样本
- 研究采用马尔可夫决策模型,比较肿瘤分子分型检测(TMC)与不检测(NT)两种策略。
- 分析采用医疗支付方视角和5年时间跨度。
- 基础病例数据取自PORTEC-3及其分子亚组分析,成本和效用数据来自公共数据库、同行评议文献和专家意见。
- 策略比较采用增量成本-效果比(ICER),效果指标为质量调整生命年(QALYs),支付意愿阈值为每QALY 100000美元,并开展敏感性分析检验模型稳健性。
主要发现
- 与NT相比,TMC具有成本效果,ICER为每QALY 25578美元;增量成本为1780美元,增量效果为0.070 QALYs。
- 单因素敏感性分析中,结果对POLE检测成本最敏感,但TMC在所有参数范围内仍保持成本效果。
关键数值与推荐
- 支付意愿阈值为每QALY 100000美元。
- TMC较NT的ICER为每QALY 25578美元,增量成本1780美元,增量效果0.070 QALYs。
临床怎么用
- 作者认为,鉴于分子分型可用于指导辅助治疗决策,这些发现支持将肿瘤分子分型检测纳入常规实践。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tumor molecular analyses in endometrial cancer (EC) includes 4 distinct subtypes: (1) POLE-mutated, (2) mismatch repair protein (MMR) deficient, (3) p53 mutant, and (4) no specific molecular profile. Recently, a sub-analysis of PORTEC-3 demonstrated notable differences in treatment response between molecular classification (MC) groups. Cost of testing is one barrier to widespread adoption of MC. Therefore, we sought to determine the cost-effectiveness of MC in patients with stage I and II high-risk EC. METHODS: A Markov decision model was developed to compare tumor molecular classification (TMC) vs. no testing (NT). A healthcare payor's perspective and 5-year time horizon were used. Base case data were abstracted from PORTEC-3 and the molecular sub-analysis. Cost and utility data were derived from public databases, peer-reviewed literature, and expert input. Strategies were compared using the incremental cost-effectiveness ratio (ICER) with effectiveness in quality-adjusted life years (QALYs) and evaluated with a willingness-to-pay threshold of $100,000 per QALY gained. Sensitivity analyses were performed to test model robustness. RESULTS: When compared to NT, TMC was cost effective with an ICER of $25,578 per QALY gained; incremental cost was $1780 and incremental effectiveness was 0.070 QALYs. In one-way sensitivity analyses, results were most sensitive to the cost of POLE testing, but TMC remained cost-effective over all parameter ranges. CONCLUSIONS: TMC in early-stage high-risk EC is cost-effective, and the model results were robust over a range of parameters. Given that MC can be used to guide adjuvant treatment decisions, these findings support adoption of TMC into routine practice.
引用
- Orellana TJ, Kim H, Beriwal S, et al. Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer. Gynecol Oncol. 2021. PMID: 34740462. doi:10.1016/j.ygyno.2021.10.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。